These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. Deal EN; Micek ST; Reichley RM; Ritchie DJ Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902 [TBL] [Abstract][Full Text] [Related]
8. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia. Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Jeong SJ; Yoon SS; Bae IK; Jeong SH; Kim JM; Lee K Diagn Microbiol Infect Dis; 2014 Oct; 80(2):130-5. PubMed ID: 25112900 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098 [TBL] [Abstract][Full Text] [Related]
11. Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa. Marra AR; Bearman GM; Wenzel RP; Edmond MB BMC Infect Dis; 2006 Aug; 6():132. PubMed ID: 16916466 [TBL] [Abstract][Full Text] [Related]
13. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415 [TBL] [Abstract][Full Text] [Related]
14. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Hirsch EB; Cottreau JM; Chang KT; Caeiro JP; Johnson ML; Tam VH Diagn Microbiol Infect Dis; 2012 Jan; 72(1):97-102. PubMed ID: 22056006 [TBL] [Abstract][Full Text] [Related]
15. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908 [TBL] [Abstract][Full Text] [Related]
16. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A; Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for the failure of treatment of Yoshida S; Suzuki K; Suzuki A; Okada H; Niwa T; Kobayashi R; Murakami N; Ogura S; Itoh Y Pharmazie; 2017 Jul; 72(7):428-432. PubMed ID: 29441942 [TBL] [Abstract][Full Text] [Related]
19. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study. Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]